Reviva Announces Positive Preliminary Topline Data for the Long-Term Open Label Extension Portion of the Phase 3 RECOVER Study Evaluating Brilaroxazine in Schizophrenia

News
1
4 Likes
2

weight gain profile?

Brilaroxazine appears to have a favorable weight gain profile compared to other antipsychotics. In clinical trials, the percentage of patients who experienced weight gain was relatively low:

  • 15 mg dose: 2.1% of patients experienced weight gain.
  • 50 mg dose: 5.9% of patients experienced weight gain.
  • Placebo: 2.9% of patients experienced weight gain.

This is a significant improvement over some currently prescribed antipsychotics like aripiprazole, brexpiprazole, and cariprazine, which tend to have higher rates of weight gain.

3 Likes
3

https://www.fiercebiotech.com/biotech/revivas-antipsychotic-shows-promise-against-schizophrenia-symptoms-year-long-study

2 Likes
4

This looks like a very promising drug. Am waiting for the more extensive bottom line results of the trial.
The company is close to bankrupt and has announced a plan to issue new shares. The money would finance the final phase 3 trial of the drug. So far, no pharma company has offered to acquire Reviva.

4 Likes
5

In the trial, there was a 4.5 drop in negative symptoms of the PANSS score.

  • PANSS Negative Symptoms: 4.5-point decrease (19.5 →15.0), p ≤ 0.0001
2 Likes